Jay Bradner (Jeff Rumans for Endpoints News)
September 21, 2021 01:15 AM EDTUpdated 09:26 AM
Deals
Cell/Gene Tx

Div­ing deep­er in­to in­her­it­ed reti­nal dis­or­ders, No­var­tis gob­bles up an­oth­er bite-sized op­to­ge­net­ics biotech

John Carroll

Editor & Founder

Right about a year ago, a No­var­tis team led by Jay Brad­ner and Cyn­thia Grosskreutz at NI­BR swooped in to scoop up a Cam­bridge, MA …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

In­tel­lia to cut work­force by 27%, plans com­mer­cial­iza­tion of first CRISPR ther­a­py in 2027

Lil­ly ven­tures in­to pul­monary fi­bro­sis with start­up Me­di­ar

John Maraganore turns to ex-Al­ny­lam col­league to lead his lat­est RNAi bet; Amy­lyx names com­mer­cial chief

With $120M, GSK-al­lied Ouro Med­i­cines throws its hat in­to bur­geon­ing TCE ring

An­oth­er biotech scoops up as­set from Chi­na-based Keymed and nabs $180M

Re­pare paus­es late-stage plans, reshuf­fles pipeline in ef­fort to cut costs

A service from the Financial Times